The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats.
- Published in:
- Liver International, 2015, v. 35, n. 2, p. 326, doi. 10.1111/liv.12472
- By:
- Publication type:
- Article
Works matching DE "DROXIDOPA"
Results: 26
1
2
A theoretical study of solvent effects on the characteristics of the intramolecular hydrogen bond in Droxidopa.
- Published in:
- Journal of Chemical Sciences, 2015, v. 127, n. 6, p. 1007, doi. 10.1007/s12039-015-0858-2
- By:
- Publication type:
- Article
3
Analysis of number needed to treat for droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
- Published in:
- 2016
- By:
- Publication type:
- journal article
4
Accidental Overdose of Droxidopa in Parkinson's Disease-related Orthostatic Hypotension.
- Published in:
- Movement Disorders Clinical Practice, 2017, v. 4, n. 2, p. 279, doi. 10.1002/mdc3.12390
- By:
- Publication type:
- Article
5
Neurogenic orthostatic hypotension - management update and role of droxidopa.
- Published in:
- Therapeutics & Clinical Risk Management, 2015, v. 11, p. 915, doi. 10.2147/TCRM.S68439
- By:
- Publication type:
- Article
6
Orthostatic hypotension: managing a difficult problem.
- Published in:
- 2015
- By:
- Publication type:
- journal article
7
Droxidopa in neurogenic orthostatic hypotension.
- Published in:
- Expert Review of Cardiovascular Therapy, 2015, v. 13, n. 8, p. 875, doi. 10.1586/14779072.2015.1057504
- By:
- Publication type:
- Article
8
Impact of the Norepinephrine Prodrug Droxidopa on the QTc Interval in Healthy Individuals.
- Published in:
- Clinical Pharmacology in Drug Development, 2018, v. 7, n. 3, p. 332, doi. 10.1002/cpdd.393
- By:
- Publication type:
- Article
9
Stability-Indicating Related Substances HPLC Method for Droxidopa and Characterization of Related Substances Using LC-MS and NMR.
- Published in:
- Journal of Chromatographic Science, 2016, v. 54, n. 10, p. 1761, doi. 10.1093/chromsci/bmw136
- By:
- Publication type:
- Article
10
Erratum to: Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
- Published in:
- 2017
- By:
- Publication type:
- Erratum
11
28TH International symposium on the autonomic nervous system.
- Published in:
- Clinical Autonomic Research, 2017, v. 27, n. 5, p. 295, doi. 10.1007/s10286-017-0462-2
- Publication type:
- Article
12
Differential diagnosis of suspected neurogenic orthostatic hypotension in a patient with Parkinson disease.
- Published in:
- 2017
- By:
- Publication type:
- Letter
13
Adding droxidopa to fludrocortisone or midodrine in a patient with neurogenic orthostatic hypotension and Parkinson disease.
- Published in:
- 2017
- By:
- Publication type:
- Letter
14
Managing neurogenic orthostatic hypotension in a patient presenting with pure autonomic failure who later developed Parkinson disease.
- Published in:
- 2017
- By:
- Publication type:
- Letter
15
Titrating droxidopa to maximize symptomatic benefit in a patient with Parkinson disease and neurogenic orthostatic hypotension.
- Published in:
- 2017
- By:
- Publication type:
- Letter
16
Initiating droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
- Published in:
- 2017
- By:
- Publication type:
- Letter
17
Adjusting droxidopa for neurogenic orthostatic hypotension in a patient with Parkinson disease.
- Published in:
- 2017
- By:
- Publication type:
- Letter
18
Defining successful treatment of neurogenic orthostatic hypotension with droxidopa in a patient with multiple system atrophy.
- Published in:
- 2017
- By:
- Publication type:
- Letter
19
Polypharmacy: droxidopa to treat neurogenic orthostatic hypotension in a patient with Parkinson disease and type 2 diabetes mellitus.
- Published in:
- 2017
- By:
- Publication type:
- Letter
20
Managing supine hypertension in a patient with non-diabetic autonomic neuropathy receiving droxidopa for neurogenic orthostatic hypotension.
- Published in:
- 2017
- By:
- Publication type:
- Letter
21
Managing neurogenic orthostatic hypotension with droxidopa in a patient with Parkinson disease, atrial fibrillation, and hypertension.
- Published in:
- 2017
- By:
- Publication type:
- Letter
22
Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn?
- Published in:
- 2017
- By:
- Publication type:
- Editorial
23
Meta-analysis of the safety and efficacy of droxidopa for neurogenic orthostatic hypotension.
- Published in:
- Clinical Autonomic Research, 2016, v. 26, n. 3, p. 171, doi. 10.1007/s10286-016-0349-7
- By:
- Publication type:
- Article
24
Integrated analysis of droxidopa trials for neurogenic orthostatic hypotension.
- Published in:
- 2017
- By:
- Publication type:
- journal article
25
Impact of drugs on intradialytic hypotension: Antihypertensives and vasoconstrictors.
- Published in:
- 2017
- By:
- Publication type:
- journal article
26
Comparison of the Pharmacokinetics of Droxidopa After Dosing in the Fed Versus Fasted State and with 3-Times-Daily Dosing in Healthy Elderly Subjects.
- Published in:
- Drugs in R&D, 2018, v. 18, n. 1, p. 77, doi. 10.1007/s40268-018-0226-z
- By:
- Publication type:
- Article